Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Other Accumulated Expenses (2019 - 2025)

Angiodynamics (ANGO) has disclosed Other Accumulated Expenses for 12 consecutive years, with $6.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses fell 25.08% year-over-year to $6.7 million, compared with a TTM value of $6.7 million through Nov 2025, down 25.08%, and an annual FY2025 reading of $7.4 million, down 2.51% over the prior year.
  • Other Accumulated Expenses was $6.7 million for Q4 2025 at Angiodynamics, down from $8.7 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $10.3 million in Q1 2024 and bottomed at $1.8 million in Q4 2023.
  • Average Other Accumulated Expenses over 5 years is $4.5 million, with a median of $2.6 million recorded in 2022.
  • The sharpest move saw Other Accumulated Expenses soared 408.79% in 2024, then crashed 43.88% in 2025.
  • Year by year, Other Accumulated Expenses stood at $2.6 million in 2021, then increased by 0.66% to $2.6 million in 2022, then tumbled by 31.83% to $1.8 million in 2023, then skyrocketed by 408.79% to $9.0 million in 2024, then decreased by 25.08% to $6.7 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for ANGO at $6.7 million in Q4 2025, $8.7 million in Q3 2025, and $7.4 million in Q2 2025.